TY - JOUR
T1 - Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial)
T2 - Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))
AU - Choueiri, Toni K.
AU - Hessel, Colin
AU - Halabi, Susan
AU - Sanford, Ben
AU - Michaelson, M. Dror
AU - Hahn, Olwen
AU - Walsh, Meghara
AU - Olencki, Thomas
AU - Picus, Joel
AU - Small, Eric J.
AU - Dakhil, Shaker
AU - Feldman, Darren R.
AU - Mangeshkar, Milan
AU - Scheffold, Christian
AU - George, Daniel
AU - Morris, Michael J.
N1 - Publisher Copyright:
© 2018 The Author(s)
PY - 2018/11
Y1 - 2018/11
N2 - The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined) As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group). The authors would like to apologise for any inconvenience caused.
AB - The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined) As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group). The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85054008620&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2018.09.022
DO - 10.1016/j.ejca.2018.09.022
M3 - Comment/debate
C2 - 30270112
AN - SCOPUS:85054008620
SN - 0959-8049
VL - 103
SP - 287
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -